Regencor Inc. a US-based life sciences company, announced on Wednesday that it has added Philip Janiak, PhD and Ken Mahaffey, MD to its Scientific Advisory Board.
Dr Mahaffey serves as a professor of cardiovascular medicine at the Stanford University School of Medicine. His main area of research is the design and implementation of multicentre clinical trials, concentrating on analyses of important clinical cardiac outcome measures utilising large patient databases. He has headed or served on the Executive Committees for many cardiovascular outcome trials, more than 125 Clinical Endpoint Committees, and multiple Data Safety Monitoring Boards. Dr Mahaffey has also served with the FDA and is a consultant for the Endocrinologic and Metabolic Drugs Advisory Committee.
Dr Janiak started his career at Servier and was the head of Cardiovascular Research at Sanofi. He has extensive experience in the management of international R&D groups and in heading multiple research collaborations with biopharmaceutical companies such as MyoKardia, and academic institutions such as IMI. Currently, Dr Janiak is the CEO of Corteria Pharmaceuticals.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT